PDCD1 and non-small cell lung carcinoma: Immunotherapy, particularly, the use of immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand PD-L1, has become a key treatment for driver-negative advanced NSCLC [4–7].